Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease
Diabetologia · 2026-07 · 69 (7) · 2073-2087
DOI: 10.1007/s00125-026-06730-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologia, online erschienen am 21.04.2026. Verfasst von Domenico Tricò und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. domenico.trico@unipi.it. Hauptthemen laut MEDLINE: Glucose, Fatty Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca, National Health and Medical Research Council, Adelaide University.
Abstract (Originalsprache)
Aims/hypothesis Hepatic glucose flux plays a crucial role in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), promoting de novo lipogenesis, inflammation and fibrosis. This study aimed to evaluate the kinetics of oral glucose absorption and one of its key modulators, gastric emptying, in individuals with early-stage MASLD vs matched control individuals.
Methods
We quantified glucose metabolic fluxes during a 75 g OGTT using stable isotopes in individuals with MASLD without fibrosis and in healthy control individuals. In a separate cohort, we measured the gastric emptying rate using the 13 C-acetate breath test during an OGTT and estimated hepatic steatosis risk.
Results
Compared with the control group, in the MASLD group the rate of appearance of oral ingested glucose (RaO) normalised to body weight was 34% higher at 1 h post-OGTT (+318±142 µmol/kg, p =0.031), resulting in a 52% increase in total glucose absorption (+6.4±1.8 g, p =0.001). Participants with MASLD exhibited reduced glucose clearance relative to plasma insulin levels but preserved post-load suppression of endogenous glucose production, indicating peripheral rather than hepatic insulin resistance. Among glucose metabolic fluxes, RaO showed the strongest association with prevalent MASLD, with each 1-SD increase in 1 h RaO being associated with fivefold higher odds of MASLD (OR 4.99 [95% CI 1.44, 31.57], p =0.036), independent of potential confounders. Gastric emptying rate was not associated with hepatic steatosis risk. Conclusions/interpretation Oral glucose absorption is augmented in individuals with MASLD without fibrosis, apparently unrelated to accelerated gastric emptying. This metabolic alteration may represent an early driver of MASLD pathogenesis, preceding hepatic insulin resistance. Future research should investigate whether modulation of intestinal glucose absorption confers therapeutic benefits in MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. domenico.trico@unipi.it.
- Laboratory of Metabolism, Nutrition and Atherosclerosis, University of Pisa, Pisa, Italy. domenico.trico@unipi.it.
- School of Medicine and Centre of Research Excellence in Translating Nutritional Science to Good Health, College of Health, Adelaide University, Adelaide, SA, Australia. tongzhi.wu@adelaide.edu.au.
- Laboratory of Metabolism, Nutrition and Atherosclerosis, University of Pisa, Pisa, Italy.
- Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Förderung
- Ministero dell'Università e della Ricerca
- National Health and Medical Research Council
- Adelaide University
Zitieren
APA
Tricò, D., Wu, T., Cimbalo, N., Chiriacò, M., Xie, C., Sacchetta, L., Nesti, L., Gallo, S., Santoni, L., Masoni, M. C., Petralli, G., Fiorentino, T. V., Bizzotto, R., Scozzaro, M. T., Frascerra, S., Baldi, S., Brunetto, M. R., Mari, A., Rayner, C. K., & Natali, A. (2026). Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease. Diabetologia, 69(7), 2073-2087. https://doi.org/10.1007/s00125-026-06730-5
Vancouver
Tricò D, Wu T, Cimbalo N, Chiriacò M, Xie C, Sacchetta L, et al. Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease. Diabetologia. 2026;69(7):2073-2087. doi:10.1007/s00125-026-06730-5
BibTeX
@article{Tric2026,
author = {Tricò, Domenico and Wu, Tongzhi and Cimbalo, Noemi and Chiriacò, Martina and Xie, Cong and Sacchetta, Luca and Nesti, Lorenzo and Gallo, Simone and Santoni, Lorenza and Masoni, Maria C and Petralli, Giovanni and Fiorentino, Teresa V and Bizzotto, Roberto and Scozzaro, Maria T and Frascerra, Silvia and Baldi, Simona and Brunetto, Maurizia R and Mari, Andrea and Rayner, Christopher K and Natali, Andrea},
title = {Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease},
journal = {Diabetologia},
year = {2026},
volume = {69},
number = {7},
pages = {2073--2087},
doi = {10.1007/s00125-026-06730-5}
}
EUVIMED